JPMorgan Chase & Co. Acquires Shares of 35,713 Genocea Biosciences, Inc. (NASDAQ:GNCA)

JPMorgan Chase & Co. acquired a new position in shares of Genocea Biosciences, Inc. (NASDAQ:GNCA) during the first quarter, Holdings Channel reports. The firm acquired 35,713 shares of the biotechnology company’s stock, valued at approximately $217,000.

Separately, Keybank National Association OH purchased a new position in Genocea Biosciences during the first quarter worth approximately $147,000. Institutional investors and hedge funds own 54.23% of the company’s stock.

Genocea Biosciences, Inc. (GNCA) opened at 5.04 on Friday. Genocea Biosciences, Inc. has a 52-week low of $3.28 and a 52-week high of $7.29. The stock has a 50 day moving average of $5.32 and a 200-day moving average of $5.50. The company’s market capitalization is $143.65 million.

Genocea Biosciences (NASDAQ:GNCA) last announced its quarterly earnings data on Thursday, May 4th. The biotechnology company reported ($0.48) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.54) by $0.06. On average, equities research analysts anticipate that Genocea Biosciences, Inc. will post ($1.91) earnings per share for the current fiscal year.

TRADEMARK VIOLATION WARNING: “[[title]]” was reported by [[site]] and is owned by of [[site]]. If you are reading this article on another domain, it was stolen and reposted in violation of United States and international trademark & copyright laws. The correct version of this article can be read at [[permalink]].

GNCA has been the subject of a number of analyst reports. Zacks Investment Research lowered shares of Genocea Biosciences from a “buy” rating to a “hold” rating in a research report on Tuesday, May 30th. ValuEngine lowered shares of Genocea Biosciences from a “hold” rating to a “sell” rating in a research report on Tuesday, August 1st. Piper Jaffray Companies restated an “overweight” rating and issued a $18.00 price objective (up from $17.00) on shares of Genocea Biosciences in a research report on Tuesday, July 25th. Cowen and Company restated an “outperform” rating and issued a $40.00 price objective on shares of Genocea Biosciences in a research report on Tuesday, July 25th. Finally, Needham & Company LLC upgraded shares of Genocea Biosciences from a “hold” rating to a “buy” rating and set a $12.00 price objective for the company in a research report on Monday, July 24th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and five have assigned a buy rating to the company. The company presently has an average rating of “Buy” and an average target price of $16.52.

In related news, CFO Jonathan Poole sold 45,000 shares of the business’s stock in a transaction that occurred on Monday, July 24th. The stock was sold at an average price of $6.00, for a total transaction of $270,000.00. Following the completion of the transaction, the chief financial officer now directly owns 84,247 shares in the company, valued at approximately $505,482. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Insiders own 6.70% of the company’s stock.

Genocea Biosciences Company Profile

Genocea Biosciences, Inc, is harnessing the power of T cell immunity to develop vaccines and immunotherapies company. The Company uses its discovery platform, AnTigen Lead Acquisition System (ATLAS), to design vaccines and immunotherapies that act, in part, through T cell (or cellular) immune responses.

Want to see what other hedge funds are holding GNCA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Genocea Biosciences, Inc. (NASDAQ:GNCA).